Last updated: May 24, 2026
Suppliers for the Pharmaceutical Drug Bumetanide: Who Manufactures API and Finished Dose, and What Procurement Risks Matter?
Bumetanide supply chains split into two layers: (1) active pharmaceutical ingredient (API) manufacturers that produce bumetanide, and (2) finished-dose manufacturers (tablets, oral solutions, injectables where available). Public sourcing for bumetanide is fragmented across jurisdictions and often changes with plant approvals, regulatory status, and product discontinuations.
Because bumetanide is not a globally uniform branded product with one single commercial dossier, “suppliers” should be treated as (a) API producers and (b) listed FDA/EMA marketing authorization holders for each dosage form and strength.
No authoritative dataset was provided in the prompt (e.g., Orange Book listings, FDA drug product database extract, WHO prequalification register, EMA EPAR/authorized manufacturer lists), so a complete, accurate supplier table cannot be produced to the standard required for R&D, licensing, litigation, or procurement decisions.
What companies supply bumetanide API to generic and branded markets?
Featured snippet answer: Bumetanide API is supplied by a set of specialized generic/API manufacturers whose identities vary by jurisdiction, dosage form, and regulatory approvals; supplier lists require Orange Book and/or EMA/FDA manufacturing site evidence to be complete.
API sourcing patterns that drive supplier selection
- API is typically sourced through contract manufacturing and controlled by DMF/ASMF submissions in each target market.
- Suppliers change when a site loses product approvals, fails inspections, or shifts focus to higher-volume diuretics.
Where to verify API suppliers (data-dependent)
- FDA Orange Book for specific product-and-NDC combinations (lists approved drug product manufacturers, not always API sites).
- FDA DMF/ASMF linking to API manufacturers requires dossier-level traceability.
- EMA authorizations and EPAR assessment reports list manufacturing sites for the finished product, not always the API.
Which finished-dose manufacturers produce bumetanide tablets, oral solutions, or injections?
Featured snippet answer: Finished-dose manufacturers for bumetanide depend on dosage form and the specific NDC/marketing authorization; accurate identification requires linking each product strength to an FDA/EMA listed manufacturer and manufacturing site.
Dosage form affects supplier mapping
- Tablets vs. oral solution vs. injectable formats often have different manufacturing networks.
- Some markets rely on one or two suppliers per format due to lower demand and higher compliance burden.
What is the Orange Book status of bumetanide, and how does it determine supplier eligibility?
Featured snippet answer: Orange Book status does not identify API suppliers directly; it determines which finished-dose products are FDA-approved and which manufacturer is authorized for each NDC/strength.
Why Orange Book data matters for procurement
- Orange Book confirms FDA approval status and patent/exclusivity listings for each product.
- It supports supplier due diligence by mapping to the FDA-approved label and the authorized manufacturer(s).
Which bumetanide manufacturers face FDA regulatory or quality scrutiny?
Featured snippet answer: Quality risk is supplier- and plant-specific; assessing regulatory scrutiny requires inspection history, recall records, and current FDA/EMA compliance status by manufacturing site.
Procurement risk signals to screen by supplier site
- FDA inspection outcomes by facility
- Recalls and field actions associated with product lots
- Changes in manufacturing method or site transfers
How many bumetanide generic suppliers exist, and what drives concentration?
Featured snippet answer: The number of suppliers is limited by lower global sales volumes, site compliance costs, and the need to maintain validated processes for small-molecule diuretics.
Drivers of concentration
- Limited number of ASMF/DMF-capable API suppliers in certain regions
- Discontinuations and product lifecycle changes for older diuretics
- Supply interruptions due to single-site reliance for specific strengths
How does bumetanide supplier selection change by geography (US vs EU vs UK)?
Featured snippet answer: Geography changes the list of eligible finished-dose manufacturers because approvals are granted per regulatory region and manufacturing site.
Cross-border mapping constraints
- A manufacturer authorized in one region may not hold marketing authorization elsewhere.
- API approvals and finished product GMP requirements differ by region and inspection regime.
What licensing or patent factors affect bumetanide supply?
Featured snippet answer: For procurement, licensing and patent constraints affect which generic/authorized products can be marketed, not the underlying API supplier capability.
Where patents and exclusivity affect procurement
- Exclusivity can restrict entry of certain generic product applications.
- Patent litigation can delay launch of specific dosage forms or label indications.
What manufacturing/IP barriers can block bumetanide supply diversification?
Featured snippet answer: Barriers are often practical rather than theoretical: validated process requirements, impurity controls, and constrained manufacturing capacity for lower-volume SKUs.
Common diversification blockers
- Inconsistent assay/impurity profiles across API lots
- Tight control over polymorph or solid-state parameters in formulations
- Dependence on limited upstream API sources
Key Takeaways
- “Suppliers for bumetanide” must be split into API suppliers and finished-dose manufacturers, then mapped to dosage form and strength.
- Orange Book and regulatory authorization data are required to produce an accurate, litigation-grade supplier list for procurement and R&D planning.
- Without an Orange Book/NDC or EPAR/EMA/FDA dossier dataset in the prompt, a complete supplier table cannot be compiled to a standard that is actionable.
FAQs
- Which FDA-approved manufacturers make bumetanide tablets by NDC and strength?
- Can the same company supply both bumetanide API and finished tablets under cGMP?
- Do bumetanide recalls indicate manufacturing-site issues or specific lot problems only?
- How do DMF-linked API suppliers map to FDA product manufacturers for bumetanide?
- What due diligence steps reduce risk when switching bumetanide suppliers mid-project?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA databases).
- FDA Drugs@FDA. U.S. Food and Drug Administration. (Accessed via FDA databases).
- EMA European Public Assessment Reports (EPARs) and product authorization documents. European Medicines Agency. (Accessed via EMA website).
